Zusammenfassung
Das Ovarialkarzinom ist das sechsthäufigste Karzinom der Frau und wird meist erst diagnostiziert, wenn eine Peritonealkarzinose im gesamten Abdomen aufgetreten ist. Die Therapie besteht aus platinbasierter Chemotherapie und radikaler operativer Intervention mit dem Ziel vollständiger makroskopischer Tumorfreiheit. Nur wenn dies gelingt, ist, auch im fortgeschrittenen Stadium eine Heilung möglich. Patientinnen, die nach mehr als 6 Monaten nach Therapieabschluss ein Rezidiv erleiden, profitieren von einer erneuten operativen Intervention bei postoperativer Tumorfreiheit, solche mit Tumorrest nach der Rezidivoperation dagegen nicht. Es ist daher entscheidend, einen radikalen operativen Ansatz zu verfolgen, wenn hierdurch eine Prognoseverbesserung erreicht werden kann, der Patientin aber die Morbidität eines radikalen Eingriffs zu ersparen, wenn dies nicht der Fall ist. Hiervon zu trennen sind zur Symptomkontrolle notwendige palliative Eingriffe, etwa eine Stomaanlage zur Palliation bei Ileus und die Anlage permanenter Drainagen bei Magenpassagestörungen, Aszites und Pleuraerguss.
This is a preview of subscription content, log in via an institution to check access.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Literatur
Alberts DS, Liu PY, Hannigan EV et al (1996) Intraperitoneal cisplatin plus intravenous cyclophosphamide versus intravenous cisplatin plus intravenous cyclophosphamide for stage III ovarian cancer. N Engl J Med 335(26):1950–1955. https://doi.org/10.1056/NEJM199612263352603
Armstrong DK, Bundy B, Wenzel L et al (2006) Intraperitoneal cisplatin and paclitaxel in ovarian cancer. N Engl J Med 354(1):34–43. https://doi.org/10.1056/NEJMoa052985
Ayub TH, Keyver-Paik MD, Debald M et al (2015) Accumulation of ALDH1-positive cells after neoadjuvant chemotherapy predicts treatment resistance and prognosticates poor outcome in ovarian cancer. Oncotarget 6(18):16437–16448. https://doi.org/10.18632/oncotarget.4103
du Bois A, Harter P (2006) The role of surgery in advanced and recurrent ovarian cancer. Ann Oncol 17(Suppl 10):x235–x240. https://doi.org/10.1093/annonc/mdl266
du Bois ASB, Meier W, Sehouli J, Pfisterer J (2006) Kommission Ovar der AGO dA-SO, NOGGO A-Oud. Ovarialkarzinom: Intraperitoneale Therapie ist nicht der neue Standard. Frauenarzt 47(6):510–512
du Bois AVI, Ferron G, Reuss A, et al (2017) The role of secondary cytoreductive surgery in recurrent ovarian cancer (OC) has not been defined by level-1 evidence. J Clin Oncol 35(suppl; abstr 5501)
Bristow RE, Puri I, Chi DS (2009) Cytoreductive surgery for recurrent ovarian cancer: a meta-analysis. Gynecol Oncol 112(1):265–274. https://doi.org/10.1016/j.ygyno.2008.08.033
van der Burg ME (2001) Advanced ovarian cancer. Curr Treat Options in Oncol 2(2):109–118
Chi DS, Eisenhauer EL, Lang J et al (2006a) What is the optimal goal of primary cytoreductive surgery for bulky stage IIIC epithelial ovarian carcinoma (EOC)? Gynecol Oncol 103(2):559–564. https://doi.org/10.1016/j.ygyno.2006.03.051
Chi DS, McCaughty K, Diaz JP et al (2006b) Guidelines and selection criteria for secondary cytoreductive surgery in patients with recurrent, platinum-sensitive epithelial ovarian carcinoma. Cancer 106(9):1933–1939. https://doi.org/10.1002/cncr.21845
Chi DS, Zivanovic O, Levinson KL et al (2010) The incidence of major complications after the performance of extensive upper abdominal surgical procedures during primary cytoreduction of advanced ovarian, tubal, and peritoneal carcinomas. Gynecol Oncol 119(1):38–42. https://doi.org/10.1016/j.ygyno.2010.05.031
Chundury A, Apicelli A, DeWees T et al (2016) Intensity modulated radiation therapy for recurrent ovarian cancer refractory to chemotherapy. Gynecol Oncol 141(1):134–139. https://doi.org/10.1016/j.ygyno.2016.02.005
Clive AO, Jones HE, Bhatnagar R, Preston NJ, Maskell N (2016) Interventions for the management of malignant pleural effusions: a network meta-analysis. Cochrane Database Syst Rev (5):CD010529. https://doi.org/10.1002/14651858.CD010529.pub2
Coupe NA, Cox K, Clark K et al (2013) Outcomes of permanent peritoneal ports for the management of recurrent malignant ascites. J Palliat Med 16(8):938–940. https://doi.org/10.1089/jpm.2012.0535
Davies HE, Mishra EK, Kahan BC et al (2012) Effect of an indwelling pleural catheter vs chest tube and talc pleurodesis for relieving dyspnea in patients with malignant pleural effusion: the TIME2 randomized controlled trial. JAMA 307(22):2383–2389. https://doi.org/10.1001/jama.2012.5535
Feller-Kopman D, Berkowitz D et al (2007) Large-volume thoracentesis and the risk of reexpansion pulmonary edema. Ann Thorac Surg 84(5):1656–1661. https://doi.org/10.1016/j.athoracsur.2007.06.038
Giorda G, Gadducci A, Lucia E et al (2014) Prognostic role of bowel involvement in optimally cytoreduced advanced ovarian cancer: a retrospective study. J Ovarian Res 7:72. https://doi.org/10.1186/1757–2215–7–72
Grimm C, Harter P, Alesina PF et al (2017) The impact of type and number of bowel resections on anastomotic leakage risk in advanced ovarian cancer surgery. Gynecol Oncol. https://doi.org/10.1016/j.ygyno.2017.06.007
Harter P, du Bois A, Hahmann M et al (2006) Surgery in recurrent ovarian cancer: the Arbeitsgemeinschaft Gynaekologische Onkologie (AGO) DESKTOP OVAR trial. Ann Surg Oncol 13(12):1702–1710. https://doi.org/10.1245/s10434-006–9058-0
Harter P, Gnauert K, Hils R et al (2007) Pattern and clinical predictors of lymph node metastases in epithelial ovarian cancer. Int J Gynecol Cancer 17(6):1238–1244. https://doi.org/10.1111/j.1525–1438.2007.00931.x
Harter P, Sehouli J, Reuss A et al (2011) Prospective validation study of a predictive score for operability of recurrent ovarian cancer: the Multicenter Intergroup Study DESKTOP II. A project of the AGO Kommission OVAR, AGO Study Group, NOGGO, AGO-Austria, and MITO. Int J Gynecol Cancer 21(2):289–295. https://doi.org/10.1097/IGC.0b013e31820aaafd
Harter P, Mahner S, Hilpert F et al (2013) Statement by the Kommission OVAR of the AGO Study Group on the Use of HIPEC (Hyperthermic Intraperitoneal Chemotherapy) to treat primary and recurrent ovarian cancer. Geburtsh Frauenheilkd 73(3):221–223. https://doi.org/10.1055/s-0032–1328320
Harter PSJ, Lorusso D, Reuss A, et al (2017) LION: Lymphadenectomy In Ovarian Neoplasms. A prospective randomized AGO study group led gynecologic cancer intergroup trial. J Clin Oncol 35(suppl; abstr 5500)
Heintz AP, Odicino F, Maisonneuve P et al (2006) Carcinoma of the ovary. FIGO 6th annual report on the results of treatment in gynecological cancer. Int J Gynaecol Obstet 95(Suppl 1):S161–S192. https://doi.org/10.1016/S0020-7292(06)60033-7
Heiss MM, Murawa P, Koralewski P et al (2010) The trifunctional antibody catumaxomab for the treatment of malignant ascites due to epithelial cancer: results of a prospective randomized phase II/III trial. Int J Cancer 127(9):2209–2221. https://doi.org/10.1002/ijc.25423
Helm CW (2009) The role of hyperthermic intraperitoneal chemotherapy (HIPEC) in ovarian cancer. Oncologist 14(7):683–694. https://doi.org/10.1634/theoncologist.2008-0275. theoncologist.2008-0275 [pii]
Helm CW (2012) Ports and complications for intraperitoneal chemotherapy delivery. BJOG 119(2):150–159. https://doi.org/10.1111/j.1471-0528.2011.03179.x
Hope JM, Pothuri B (2013) The role of palliative surgery in gynecologic cancer cases. Oncologist 18(1):73–79. https://doi.org/10.1634/theoncologist.2012-0328
Hunt BM, Farivar AS, Vallieres E et al (2012) Thoracoscopic talc versus tunneled pleural catheters for palliation of malignant pleural effusions. Ann Thorac Surg 94(4):1053–1057; discussion 7–9. https://doi.org/10.1016/j.athoracsur.2012.01.103
Kehoe S, Hook J, Nankivell M et al (2015) Primary chemotherapy versus primary surgery for newly diagnosed advanced ovarian cancer (CHORUS): an open-label, randomised, controlled, non-inferiority trial. Lancet 386(9990):249–257. https://doi.org/10.1016/S0140-6736(14)62223–6
Keyver-Paik MD, Zivanovic O, Rudlowski C et al (2013) Interval debulking surgery in patients with Federation of Gynecology and Obstetrics (FIGO) stage IIIC and IV ovarian cancer. Onkologie 36(6):324–332. https://doi.org/10.1159/000351256 000351256
Keyver-Paik MD, Abramian A, Domrose C et al (2015) Integrated care in ovarian cancer „IgV Ovar“: results of a German pilot for higher quality in treatment of ovarian cancer. J Cancer Res Clin Oncol. https://doi.org/10.1007/s00432-015–2055–6
Kuhn W, Rutke S, Spathe K et al (2001) Neoadjuvant chemotherapy followed by tumor debulking prolongs survival for patients with poor prognosis in International Federation of Gynecology and Obstetrics Stage IIIC ovarian carcinoma. Cancer 92(10):2585–2591. https://doi.org/10.1002/1097-0142(20011115)92
Los G, Mutsaers PH, Lenglet WJ et al (1990) Platinum distribution in intraperitoneal tumors after intraperitoneal cisplatin treatment. Cancer Chemother Pharmacol 25(6):389–394
Markman M, Bundy BN, Alberts DS, Fowler JM, Clark-Pearson DL, Carson LF et al (2001) Phase III trial of standard-dose intravenous cisplatin plus paclitaxel versus moderately high-dose carboplatin followed by intravenous paclitaxel and intraperitoneal cisplatin in small-volume stage III ovarian carcinoma: an intergroup study of the Gynecologic Oncology Group, Southwestern Oncology Group, and Eastern Cooperative Oncology Group. J Clin Oncol 19(4):1001–1007
Narayanan G, Pezeshkmehr A, Venkat S et al (2014) Safety and efficacy of the PleurX catheter for the treatment of malignant ascites. J Palliat Med 17(8):906–912. https://doi.org/10.1089/jpm.2013.0427
Oseledchyk A, Abramian A, Kaiser C et al (2014) Total or subtotal colectomy in patients undergoing surgery for primary or recurrent epithelial ovarian cancer. Oncol Res treat 37(9):448–454. https://doi.org/10.1159/000366249
Oseledchyk A, Hunold LE, Mallmann MR et al (2016) Impact of extended primary surgery on suboptimally operable patients with advanced ovarian cancer. Int J Gynecol Cancer 26(5):873–883. https://doi.org/10.1097/IGC.0000000000000707
Polcher M, Mahner S, Ortmann O et al (2009) Neoadjuvant chemotherapy with carboplatin and docetaxel in advanced ovarian cancer – a prospective multicenter phase II trial (PRIMOVAR). Oncol Rep 22(3):605–613
Rahman NM, Pepperell J, Rehal S et al (2015) Effect of opioids vs NSAIDs and larger vs smaller chest tube size on pain control and pleurodesis efficacy among patients with malignant pleural effusion: the TIME1 randomized clinical trial. JAMA 314(24):2641–2653. https://doi.org/10.1001/jama.2015.16840
di Re F, Baiocchi G, Fontanelli R et al (1996) Systematic pelvic and paraaortic lymphadenectomy for advanced ovarian cancer: prognostic significance of node metastases. Gynecol Oncol 62(3):360–365. https://doi.org/10.1006/gyno.1996.0249
Rose PG, Nerenstone S, Brady MF et al (2004) Secondary surgical cytoreduction for advanced ovarian carcinoma. N Engl J Med 351(24):2489–2497. https://doi.org/10.1056/NEJMoa041125
Sabur NF, Chee A, Stather DR et al (2013) The impact of tunneled pleural catheters on the quality of life of patients with malignant pleural effusions. Respiration 85(1):36–42. https://doi.org/10.1159/000342343
Schroder L, Rudlowski C, Kutkuhn P et al (2016) Impact of open laparoscopy in patients under suspicion of ovarian cancer. Anticancer Res 36(7):3459–3464
Sehouli J, Savvatis K, Braicu EI, Schmidt SC, Lichtenegger W, Fotopoulou C (2010) Primary versus interval debulking surgery in advanced ovarian cancer: results from a systematic single-center analysis. Int J Gynecol Cancer 20(8):1331–1340. https://doi.org/10.1111/IGC.0b013e3181f15714
Shaw P, Agarwal R (2004) Pleurodesis for malignant pleural effusions. Cochrane Database Syst Rev (1):CD002916. https://doi.org/10.1002/14651858.CD002916.pub2.
Stephenson J, Gilbert J (2002) The development of clinical guidelines on paracentesis for ascites related to malignancy. Palliat Med 16(3):213–218. https://doi.org/10.1191/0269216302pm509oa
Tremblay A, Mason C, Michaud G (2007) Use of tunnelled catheters for malignant pleural effusions in patients fit for pleurodesis. Eur Respir J 30(4):759–762. https://doi.org/10.1183/09031936.00164706
Van Driel WSK, Schagen van Leeuwen J., Schreuder H., et al (2017) A phase 3 trial of hyperthermic intraperitoneal chemotherapy (HIPEC) for ovarian cancer. J Clin Oncol 35(suppl; abstr 5519)
Vergote I, Trope CG, Amant F et al (2010) Neoadjuvant chemotherapy or primary surgery in stage IIIC or IV ovarian cancer. N Engl J Med 363(10):943–953. https://doi.org/10.1056/NEJMoa0908806
Winter WE 3rd, Maxwell GL, Tian C et al (2007) Prognostic factors for stage III epithelial ovarian cancer: a Gynecologic Oncology Group Study. J Clin Oncol 25(24):3621–3627. https://doi.org/10.1200/JCO.2006.10.2517
Wong BC, Cake L, Kachuik L, Amjadi K (2015) Indwelling peritoneal catheters for managing malignancy-associated ascites. J Palliat Care 31(4):243–249. https://doi.org/10.1177/082585971503100406
Wright AA, Bohlke K, Armstrong DK et al (2016) Neoadjuvant chemotherapy for newly diagnosed, advanced ovarian cancer: Society of Gynecologic Oncology and American Society of Clinical Oncology Clinical Practice Guideline. J Clin Oncol 34(28):3460–3473. https://doi.org/10.1200/JCO.2016.68.6907
Zivanovic O, Abramian A, Kullmann M et al (2014) HIPEC ROC I: a phase I study of cisplatin administered as hyperthermic intraoperative intraperitoneal chemoperfusion followed by postoperative intravenous platinum-based chemotherapy in patients with platinum-sensitive recurrent epithelial ovarian cancer. Int J Cancer. https://doi.org/10.1002/ijc.29011
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2019 Springer-Verlag GmbH Deutschland, ein Teil von Springer Nature
About this chapter
Cite this chapter
Kuhn, W., Keyver-Paik, MD. (2019). Palliative Chirurgie des Ovarialkarzinoms. In: Ghadimi, M., Homayounfar, K., Kalff, J. (eds) Palliative Viszeralchirurgie. Springer, Berlin, Heidelberg. https://doi.org/10.1007/978-3-662-57362-4_25
Download citation
DOI: https://doi.org/10.1007/978-3-662-57362-4_25
Published:
Publisher Name: Springer, Berlin, Heidelberg
Print ISBN: 978-3-662-57361-7
Online ISBN: 978-3-662-57362-4
eBook Packages: Medicine (German Language)